|Other names||ALD403, eeptinezumab-jjmr|
|Drug class||Calcitonin gene-related peptide antagonist|
|Chemical and physical data|
|Molar mass||143283.20 g·mol−1|
Eptinezumab, sold under the brand name Vyepti, is a medication for the preventive treatment of migraine in adults. It is a monoclonal antibody that targets calcitonin gene-related peptides (CGRP) alpha and beta. It is administered by intravenous infusion every three months.
The U.S. Food and Drug Administration (FDA) approved eptinezumab based primarily on evidence from two clinical trials (Trial 1/ NCT02559895 and Trial 2/ NCT02974153) of 1741 subjects with chronic or episodic migraine headaches. Trials were conducted at 212 sites in United States, Georgia, Russia, Ukraine and European Union.
Trial 1 enrolled subjects with a history of episodic migraine headaches and Trial 2 enrolled subjects with chronic migraine headaches. Subjects were assigned to receive one of two doses of eptinezumab or placebo injections every three months for a total of twelve months in Trial 1, and for a total of 6 months in Trial 2. Neither the subjects nor the health care providers knew which treatment was being given until the trial was completed.
The benefit of eptinezumab in comparison to placebo was assessed based on the change in the number of migraine days per month during the first 3-month treatment period.
- Other anti-migraine antibodies blocking the calcitonin gene-related peptide (CGRP) pathway
- "Alder BioPharmaceuticals Initiates PROMISE 2 Pivotal Trial of Eptinezumab for the Prevention of Migraine". Alder Biopharmaceuticals. 28 November 2016.
- "Vyeptitm (eptinezumab-jjmr) injection, for intravenous use" (PDF). U.S. Food and Drug Administration (FDA). Retrieved 24 February 2020.
- Dodick DW, Goadsby PJ, Silberstein SD, Lipton RB, Olesen J, Ashina M, et al. (November 2014). "Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial". The Lancet. Neurology. 13 (11): 1100–1107. doi:10.1016/S1474-4422(14)70209-1. PMID 25297013. S2CID 206161999.
- "International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO Drug Information. WHO. 31 (1). 2017.
- "Vyepti: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 24 February 2020.
- "Drug Trials Snapshots: VYEPTI". U.S. Food and Drug Administration (FDA). 21 February 2020. Retrieved 17 March 2020. This article incorporates text from this source, which is in the public domain.
- "Eptinezumab". Drug Information Portal. U.S. National Library of Medicine.